Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 9NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7Sarcoma 6Gliosarcoma 6Glioblastoma 6Multiple Myeloma 5Hematologic Neoplasms 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Rhabdomyosarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Sirolimus 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphangioleiomyomatosis × Sirolimus × Clear all
NCT03304678 2026-02-18

Discovery of Sirolimus Sensitive Biomarkers in Blood

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
33 enrolled 6 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡